Table 1.

Routes to escape from targeted therapy in cancer

• Genetic variation	i. ‘Target’ segregated in sub-clones, not truncal
	ii. ‘Target’ mutated and impervious to drugs
• Epigenetic plasticity	i. Inhibited target bypassed by signal redundancy in network
	ii. Quiescent/dormant stem cells intrinsically resistant